In a post on X (formerly Twitter), Neuralink described the trial as “an important first step towards restoring not only digital freedom but also physical freedom.” The study is named the CONVOY Study.
The announcement follows Neuralink’s recent statement that it plans to launch its first international clinical trial in Canada.
